HSP90 as a marker of progression in melanoma
- PMID: 18037622
- DOI: 10.1093/annonc/mdm545
HSP90 as a marker of progression in melanoma
Abstract
Background: HSP90 chaperones molecules critical for cell survival and malignant progression, including mutated B-raf. HSP90-targeting agents are in clinical trials. No large studies have been conducted on expression of HSP90 in melanomas.
Materials and methods: Tissue microarrays containing 414 nevi, 198 primary and 270 metastatic melanomas were assessed using our automated quantitative analysis (AQUA) method of in situ protein measurement; we use S-100 to define pixels as melanocytes (tumor mask) within the array spot, and measure HSP90 expression within the mask using Cy5-conjugated antibodies.
Results: HSP90 expression was higher in melanomas than nevi (P < 0.0001) and higher in metastatic than primary specimens (P < 0.0001). No association was seen between high HSP90 expression and survival in the primary or metastatic patient subsets. In primary melanomas, high HSP90 expression was associated with higher Clark level (P = 0.0167) and increased Breslow depth (P < 0.0001).
Conclusions: HSP90 expression was significantly higher in tumors than nevi and was associated with disease progression, indicating that it might be a valuable drug target in melanoma, as well as a useful diagnostic marker. Prospective studies are needed to confirm the diagnostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors.
Similar articles
-
High HSP90 expression is associated with decreased survival in breast cancer.Cancer Res. 2007 Apr 1;67(7):2932-7. doi: 10.1158/0008-5472.CAN-06-4511. Cancer Res. 2007. PMID: 17409397
-
Melanoma-associated expression of transforming growth factor-beta isoforms.Am J Pathol. 1996 Jun;148(6):1887-94. Am J Pathol. 1996. PMID: 8669474 Free PMC article.
-
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.Cancer Res. 2004 Dec 1;64(23):8773-7. doi: 10.1158/0008-5472.CAN-04-1387. Cancer Res. 2004. PMID: 15574790
-
Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin.J Cutan Pathol. 1997 Oct;24(9):533-42. doi: 10.1111/j.1600-0560.1997.tb01457.x. J Cutan Pathol. 1997. PMID: 9404850 Review.
-
Biomarkers in melanoma.Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi8-13. doi: 10.1093/annonc/mdp251. Ann Oncol. 2009. PMID: 19617299 Free PMC article. Review.
Cited by
-
Fabrication of Paclitaxel and 17AAG-loaded Poly-ε-Caprolactone Nanoparticles for Breast Cancer Treatment.J Pharm Drug Deliv Res. 2021 Jan;10(1):196. Epub 2021 Jan 11. J Pharm Drug Deliv Res. 2021. PMID: 33681397 Free PMC article.
-
Heat shock proteins in multiple myeloma.Oncotarget. 2014 Mar 15;5(5):1132-48. doi: 10.18632/oncotarget.1584. Oncotarget. 2014. PMID: 24675290 Free PMC article. Review.
-
The role of heat shock proteins in bladder cancer.Nat Rev Urol. 2013 Jul;10(7):386-95. doi: 10.1038/nrurol.2013.108. Epub 2013 May 14. Nat Rev Urol. 2013. PMID: 23670183 Review.
-
Distinct patterns of proteostasis network gene expression are associated with different prognoses in melanoma patients.Sci Rep. 2024 Jan 2;14(1):198. doi: 10.1038/s41598-023-50640-0. Sci Rep. 2024. PMID: 38167612 Free PMC article.
-
Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease.PLoS One. 2018 Apr 27;13(4):e0196469. doi: 10.1371/journal.pone.0196469. eCollection 2018. PLoS One. 2018. PMID: 29702669 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous